Post

New research · Ophthalmology
Ocular immunology and inflammation · 13h
StudyOcular immunology and inflammation · 2026

Immune Checkpoint Inhibitor-Associated Uveitis Treated with the 0.19 Mg Fluocinolone Acetonide Intravitreal Implant: Clinical Outcomes in a Retrospective Case-Series.

Víctor Llorenç, Elisabetta Miserocchi, Cristina Fonseca, Uwe Pleyer
Read paper
OphthalmologyStudy

Fluocinolone acetonide implant associated with complete inflammation resolution in 92.9% of uveitis eyes

Immune Checkpoint Inhibitor-Associated Uveitis Treated with the 0.19 Mg Fluocinolone Acetonide Intravitreal Implant: Clinical Outcomes in a Retrospective Case-Series.

Víctor Llorenç … Uwe Pleyer
Ocular immunology and inflammation · 2026
Purpose

To evaluate the effectiveness and safety of the 0.19 mg fluocinolone acetonide (fluocinolone acetonide) intravitreal implant for the management of immune checkpoint inhibitor (immune checkpoint inhibitor)-associated uveitis.

Methods

Multicenter retrospective case-series including patients who developed uveitis during immune checkpoint inhibitor therapy and were treated with a 0.19 mg fluocinolone acetonide implant.

n = 9 patients
Results
92.9%
vision-threatening eye inflammation went away completely in nearly all treated eyes
n = 9 patients
More results

Median time from immune checkpoint inhibitor initiation to uveitis onset was 5.0 months (interquartile range [IQR]: 2.0-6.0).

Best-reported visual acuity improved significantly from uveitis onset (0.79 ± 0.17 logMAR) to last follow-up (0.19 ± 0.04 logMAR; p = 0.0008).

More results

Anterior chamber cell, flare, and vitreous haze resolved in all eyes ( p < 0.001 for all comparisons).

IOP remained stable, with one transient elevation successfully controlled with topical therapy.

“
Conclusion · 1 of 2

The 0.19 mg fluocinolone acetonide intravitreal implant provided sustained control of inflammation, significant visual improvement, and reduced treatment burden in patients with immune checkpoint inhibitor-associated uveitis.

Conclusion · 2 of 2

This local therapeutic approach may facilitate continuation of systemic immunotherapy while maintaining ocular disease control.

Read paper
0 comments

No comments yet. Be the first.

Related papers

LatestFoundational
Cross-sectional
44.1%
had too much homocysteine in the blood, a far larger share than in dry AMD or healthy eyes
Cohort Study
92.3%
most laser-treated eyes had a favorable eye-structure outcome
Cohort Study
56%
lost three or more lines on the eye-chart vision test
Cohort Study
50%
older patients were more likely to lose three or more lines of vision
Study
81%
trials where mask air leaks were detected blowing toward the eyes
Cohort Study
13.5%
Central retinal artery peak blood-flow speed was 13.5% lower in diabetic patients.
Study
379 +/- 156 microm
lower thickness in the central retina, checked with an eye scan
Case Report
9 of 10 eyes
eyes had better measured vision after treatment